NASDAQ:ARTV - Nasdaq - US04317A1079 - Common Stock - Currency: USD
5.36
+0.26 (+5.1%)
The current stock price of ARTV is 5.36 USD. In the past month the price increased by 16.52%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 21.17 | 378.30B | ||
AMGN | AMGEN INC | 16.39 | 174.51B | ||
GILD | GILEAD SCIENCES INC | 25.47 | 146.22B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1683.76 | 125.39B | ||
REGN | REGENERON PHARMACEUTICALS | 15.5 | 77.34B | ||
ARGX | ARGENX SE - ADR | 231.21 | 36.10B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.66B | ||
ONC | BEIGENE LTD-ADR | N/A | 26.47B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.08B | ||
BIIB | BIOGEN INC | 9.13 | 22.01B | ||
NTRA | NATERA INC | N/A | 19.02B | ||
GMAB | GENMAB A/S -SP ADR | 24.89 | 15.34B |
Artiva Biotherapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 82 full-time employees. The company went IPO on 2024-07-19. Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. The firm's product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as LN, RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, SLE and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in class III or IV lupus nephritis (LN) and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.
ARTIVA BIOTHERAPEUTICS INC
5505 Morehouse Drive
San Diego CALIFORNIA US
Employees: 82
Company Website: https://www.artivabio.com/
Phone: 18582674467
The current stock price of ARTV is 5.36 USD. The price increased by 5.1% in the last trading session.
The exchange symbol of ARTIVA BIOTHERAPEUTICS INC is ARTV and it is listed on the Nasdaq exchange.
ARTV stock is listed on the Nasdaq exchange.
12 analysts have analysed ARTV and the average price target is 21.42 USD. This implies a price increase of 299.63% is expected in the next year compared to the current price of 5.36. Check the ARTIVA BIOTHERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ARTIVA BIOTHERAPEUTICS INC (ARTV) has a market capitalization of 130.19M USD. This makes ARTV a Micro Cap stock.
ARTIVA BIOTHERAPEUTICS INC (ARTV) currently has 82 employees.
ARTIVA BIOTHERAPEUTICS INC (ARTV) has a resistance level at 6.51. Check the full technical report for a detailed analysis of ARTV support and resistance levels.
The Revenue of ARTIVA BIOTHERAPEUTICS INC (ARTV) is expected to decline by -99.19% in the next year. Check the estimates tab for more information on the ARTV EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ARTV does not pay a dividend.
ARTIVA BIOTHERAPEUTICS INC (ARTV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.52).
The outstanding short interest for ARTIVA BIOTHERAPEUTICS INC (ARTV) is 6.58% of its float. Check the ownership tab for more information on the ARTV short interest.
ChartMill assigns a technical rating of 1 / 10 to ARTV.
ChartMill assigns a fundamental rating of 2 / 10 to ARTV. While ARTV seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ARTV reported a non-GAAP Earnings per Share(EPS) of -3.52. The EPS increased by 51.15% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -34.57% | ||
ROE | -38.81% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 85% to ARTV. The Buy consensus is the average rating of analysts ratings from 12 analysts.
For the next year, analysts expect an EPS growth of -339.32% and a revenue growth -99.19% for ARTV